Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis

Neurosciences (Riyadh). 2023 Apr;28(2):148-150. doi: 10.17712/nsj.2023.2.20220102.

Abstract

Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the limitations that affect patients' daily lives. Tremors are a significant and frequent symptom in MS patients. However, there is still a lack of evidence supporting a specific therapeutic approach for MS patients' tremors. A 41-year-old man with a history of MS is presented in this study. He exhibited stiffness and tremors at the follow-up clinic, which affected his daily activities. For his spasticity, he received intrathecal baclofen (ITB). The patient's symptoms responded well to this treatment, as both stiffness and tremors decreased. In an MS patient, ITB therapy thus unexpectedly reduced and improved tremor symptoms.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Baclofen / therapeutic use
  • Humans
  • Injections, Spinal
  • Male
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Muscle Relaxants, Central* / therapeutic use
  • Muscle Spasticity / drug therapy
  • Muscle Spasticity / etiology
  • Tremor / drug therapy
  • Tremor / etiology

Substances

  • Baclofen
  • Muscle Relaxants, Central